Cutaneous ganglioneuroma

Summary

Cutaneous ganglioneuroma (MONDO:0002293) is a disease. A subtype of skin cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cutaneous ganglioneuroma
Mondo ID	MONDO:0002293
DOID	DOID:2425
NCIT	C4481
SNOMED CT	254766004
UMLS	C0346063
MedGen	91077
GARD	0023108
Is cancer (heuristic)	no

Also known as: cutaneous ganglioneuroma · ganglioneuroma of skin · ganglioneuroma of the skin · skin ganglioneuroma

Disease family

This is a subtype of skin cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › skin cancer › cutaneous ganglioneuroma

Related subtypes (12): labium majus cancer, labia minora cancer, prepuce cancer, sweat gland cancer, skin carcinoma, malignant dermis tumor, skin meningioma, cutaneous melanoma, primary cutaneous lymphoma, CD4+/CD56+ hematodermic neoplasm, eyelid cancer, sebaceous gland cancer

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.